Log in to search using one of your social media accounts:

 

Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML)

AML, autophagy inhibition, combination therapy, ROS, DNA damage
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Available for licensing and co-development are antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).IC: NCINIH Ref. No.: E-221-2015Advantages: - Fully human antibodies (m900 or m906) targeting CD56 may offer improved properties over the humanized antibody IMGN901     Applications: - Therapeutic for the treatment of neuroblastoma - Therapeutic for the treatment of other CD56-positive cancers including small cell lung cancer, multiple myeloma, pancreatic cancer...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Publication date: November 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 11 Author(s): Kendra Sweet, Jeffrey Lancet As our general understanding regarding the complex nature of acute myeloid leukemia (AML) is expanding, so is our ability to translate this biological data into clinically relevant information. The use of whole genome and whole exome sequencing has begun to shed light on the importance of a variety of somatic mutations that are frequently identified in AML. In turn, this has allowed the field to incorporate mutational data into prognostic classifications which can guide treatment decis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our data seem to confirm the value of FLAG-Ida in this setting and might suggest its best usage as bridge therapy for patients awaiting allotransplantation. Micro-Abstract Allotransplant is crucial for improving survival in refractory/first relapsed AML patients. An overall response was achieved in 48 patients (44% of the whole group) with FLAG-Ida chemotherapy approach. 24 of 48 responders underwent allotransplantation obtaining a median OS of 60 months.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract As our general understanding regarding the complex nature of acute myeloid leukemia (AML) is expanding, so is our ability to translate this biological data into clinically relevant information. The use of whole genome and whole exome sequencing has begun to shed light on the importance of a variety of somatic mutations that are frequently identified in AML. In turn, this has allowed the field to incorporate mutational data into prognostic classifications which can guide treatment decisions. Furthermore, minimal residual disease (MRD) monitoring in AML is more commonplace as the prognostic relevance of MRD...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
The past decade has witnessed major advances in our comprehension of the biological heterogeneity of acute myeloid leukemia (AML); however, translating this knowledge into better outcomes for AML patients has lagged. Over the past year, two large, randomized phase III clinical trials with novel therapies produced positive results that are expected to lead to the first new drug approvals in AML in over 40 years.[1, 2] Many other promising drugs are currently under investigation, offering hope that even more novel treatments will be added to the armamentarium in the near future.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Racial and ethnic disparities in patients with solid malignancies have been well documented. Less is known about these disparities in patients with hematologic malignancies. With the advent of novel chemotherapeutics and targeted molecular, cellular, and immunologic therapies, it is important to identify differences in care that may lead to disparate outcomes. This review provides a critical appraisal of the empirical research on racial and ethnic disparities in incidence, survival, and outcomes in patients with hematologic malignancies. The review focuses on patients with acute myeloid leukemia, acute lymphocytic leukemia...
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Clinical Trials and Observations Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Prajwal Boddu, Nitin Jain, Farhad Ravandi, Guillermo Garcia Manero, Gautam Borthakur, Tapan Kadia, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Yesid Alvarado, Koichi Takahashi, Christopher Benton, Allison Pike, Sherry Pierce, Jorge E. Cortes, Hagop M. Kantarjian
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Kiran Naqvi, Garciela Nogueras Gonzalez, Cora Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xuelin Huang, Jorge Cortes, Hagop Kantarjian
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Naval Daver, Prajwal Boddu, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Courtney DiNardo, Marina Konopleva, Naveen Pemmaraju, Tapan Kadia, Nitin Jain, Sherry Pierce, Nawar Hussain, Jing Ning, Graciela Nogueras-Gonzalez, Sreyashi Basu, Jorge Cortes, Padmanee Sharma, Hagop Kantarjian
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myeloma